中国乙肝病毒感染者约7500万：如何破局实现“临床治愈”？

Core Insights - Hepatitis B is a significant public health issue in China, with approximately 75 million infected individuals, accounting for one-third of the global total of 260 million [1][2] - The concept of "clinical cure" for chronic hepatitis B has gained consensus, with interferon-based treatment being recognized as the preferred strategy [1][2][6] Industry Overview - The World Health Organization aims to eliminate viral hepatitis as a public health threat by 2030, targeting a 90% reduction in new infections and a 65% decrease in mortality [2] - China's hepatitis B drug market is projected to exceed 70 billion yuan by 2030, with several companies actively developing new treatments [7] Treatment Developments - Recent studies indicate that pegylated interferon alpha can significantly improve the hepatitis B surface antigen clearance rates, especially in nucleoside-experienced and inactive carriers [3][6] - The clinical cure rate for chronic hepatitis B patients treated with pegylated interferon alpha can exceed 30%, with sustained effects observed in follow-up studies [6][7] Market Dynamics - The market for hepatitis B treatments is evolving, with new drugs entering the pipeline, including long-acting interferon and siRNA therapies [7] - In Q1, a leading company reported a revenue increase of 23.48% year-on-year, driven by rapid sales growth of its key product [7]